North America to Dominate Neoantigen Cancer Vaccine Market through 2026
Rising prevalence of cancer and increasing adoption of personalized medicine to drive the growth of global neoantigen cancer vaccine market. According to TechSci Research report, “ Global Neoantigen Cancer Vaccine Market By Product (Personalized neoantigen vaccine, Off-the shelf neoantigen vaccine), By Neoantigen Type (Synthetic long peptide (SLP), Nucleic Acid, Dendritic Cell, Tumor Cell), By Route of Administration (Intravenous, Intramuscular, Transdermal, Others), By Cell (Autologous, Allogenic), By Technology (RNA sequencing, Whole genome sequencing, HLA typing), By Delivery Mechanism (Liposomes, Virosomes, Electroporation, Gene gun, Others), By Application (Lung, Melanoma, Gastrointestinal, Brain Cancer, Others), By Region, Competition, Forecast & Opportunities, 2026 ” , global neoantigen cancer vaccine market is expected to reach USD1754.44 million in 2026, growing with double-digit CAGR of 54.18% during the forecast period. Neoantigen cancer vaccines a...